<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677154</url>
  </required_header>
  <id_info>
    <org_study_id>GO40554</org_study_id>
    <nct_id>NCT03677154</nct_id>
  </id_info>
  <brief_title>Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of&#xD;
      mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy&#xD;
      in participants with a best response of stable disease or partial response, or in&#xD;
      elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in&#xD;
      combination with polatuzumab vedotin IV in elderly/unfit participants with previously&#xD;
      untreated DLBCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">September 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline through approximately 90 days after last study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria (Cohort A)</measure>
    <time_frame>6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PET-CT Objective Response Rate (ORR) at PRA According to Lugano 2014 Response Criteria as Determined by the Investigator (Cohort B)</measure>
    <time_frame>6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PET-CT ORR at PRA According to the Lugano 2014 Criteria as Determined by an Independent Review Committee (IRC) (Cohort C)</measure>
    <time_frame>6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Mosunetuzumab IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Mosunetuzumab IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Mosunetuzumab IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Mosunetuzumab IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Mosunetuzumab IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Mosunetuzumab SC</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Serum Concentration (Tmax) of Mosunetuzumab SC</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Mosunetuzumab SC</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Mosunetuzumab SC</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Mosunetuzumab SC</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Mosunetuzumab SC</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Polatuzumab Vedotin IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Polatuzumab Vedotin IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Polatuzumab Vedotin IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Polatuzumab Vedotin IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Polatuzumab Vedotin IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Infusion Concentration (Ceoi) of Polatuzumab Vedotin IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough) of Polatuzumab Vedotin IV</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET-CT Rate According to the Lugano 2014 Criteria at PRA as Determined by the Investigator (Cohorts B and C) and IRC (Cohort C)</measure>
    <time_frame>6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR), Defined as the Proportion of Participants with a Complete Response (CR) or Partial Response (PR) at PRA as Determined by the Investigator (Cohorts A and C)</measure>
    <time_frame>Baseline through 2 years after PRA (up to a total of approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best ORR (CR or PR at any time) During the Study Based on PET-CT and/or CT Scans as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)</measure>
    <time_frame>Baseline through 2 years after PRA (up to a total of approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)</measure>
    <time_frame>From the first occurrence of a documented objective response to disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Confirmed Response (DOCR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)</measure>
    <time_frame>From the first occurrence of a documented CR to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)</measure>
    <time_frame>From the first study treatment to the first occurrence of disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first study treatment to death from any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning and Fatigue (Cohorts B and C)</measure>
    <time_frame>From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in European Organization for Research and Treatment of Cancer Item Library (EORTC-IL17) Physical Functioning (Cohorts B and C)</measure>
    <time_frame>From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale (Cohorts B and C)</measure>
    <time_frame>From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC QLQ-C30 (Cohorts B and C)</measure>
    <time_frame>From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC IL17 (Cohorts B and C)</measure>
    <time_frame>From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (ADAs) to Mosunetuzumab</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin (Cohort C)</measure>
    <time_frame>At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Consolidation Therapy (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly/Unfit Previously Untreated Monotherapy (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab Intravenous (IV)</intervention_name>
    <description>Participants in cohorts A and B will receive IV mosunetuzumab.</description>
    <arm_group_label>Consolidation Therapy (Cohort A)</arm_group_label>
    <arm_group_label>Elderly/Unfit Previously Untreated Monotherapy (Cohort B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosunetuzumab Subcutaneous (SC)</intervention_name>
    <description>Participants in Cohort C will receive SC mosunetuzumab.</description>
    <arm_group_label>Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab Vedotin</intervention_name>
    <description>Participants in Cohort C will receive IV polatuzumab vedotin.</description>
    <arm_group_label>Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Participants will receive tocilizumab via IV as needed to manage severe cytokine release syndrome (CRS).</description>
    <arm_group_label>Consolidation Therapy (Cohort A)</arm_group_label>
    <arm_group_label>Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)</arm_group_label>
    <arm_group_label>Elderly/Unfit Previously Untreated Monotherapy (Cohort B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for All Cohorts&#xD;
&#xD;
          -  At least one bi-dimensionally measurable nodal lesion, defined as &gt; 1.5 cm in its&#xD;
             longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as &gt;&#xD;
             1.0 cm in its longest diameter&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2; with the&#xD;
             exception of South Korea, where participants 80 years or older with ECOG &gt;/= 2 will&#xD;
             not be eligible&#xD;
&#xD;
        Inclusion Criteria Specific to Cohort A&#xD;
&#xD;
        Participants in Cohort A must also meet the following criteria for study entry:&#xD;
&#xD;
          -  Histologically confirmed DLBCL according to World Health Organization (WHO) 2016&#xD;
             expected to express the cluster of differentiation-20 (CD20) antigen&#xD;
&#xD;
          -  One prior therapy with any systemic anthracycline-based chemoimmunotherapy containing&#xD;
             regimen for previously untreated DLBCL&#xD;
&#xD;
          -  Best response of SD or PR to prior systemic chemoimmunotherapy at the end of induction&#xD;
             treatment in accordance with the Lugano 2014 criteria&#xD;
&#xD;
        Inclusion Criteria Specific to Cohorts B and C&#xD;
&#xD;
        Participants in Cohorts B and C must also meet the following criteria for study entry:&#xD;
&#xD;
          -  Previously untreated, histologically confirmed, DLBCL according to WHO 2016&#xD;
             classification&#xD;
&#xD;
          -  Age &gt;/= 80 years, or&#xD;
&#xD;
          -  Age 65-79 years and considered ineligible for chemoimmuotherapy (R-CHOP) with at least&#xD;
             one of the following: Impairment in at least two activity of daily living (ADL)&#xD;
             components as defined in the protocol; impairment in at least two instrumental ADL&#xD;
             components as defined in the protocol; cumulative illness rating scale - geriactic&#xD;
             (CIRS-G) score of at least one cormorbidity with a severity score of 3-4 or a score of&#xD;
             2 in &gt;/= 8 comorbidities; impairment in cardiac function, renal function, liver&#xD;
             function, or other comorbidities such that the participant is unfit for full-dose&#xD;
             immunochemotherapy, such as rituximab plus cyclophosphamide, doxorubicin, vincristine,&#xD;
             and prednisone (R-CHOP)&#xD;
&#xD;
          -  Participants with an initial ECOG performance status of 3 may be considered during&#xD;
             screening if the performance status is DLBCL-related and if pre-phase treatment during&#xD;
             the screening phase (not more than 100 mg/day up to 7 days prior to Cycle 1 Day 1)&#xD;
             results in an improvement of ECOG performance status to &lt;/= 2 prior to enrollment&#xD;
&#xD;
        Exclusion Criteria for All Cohorts&#xD;
&#xD;
        Participants who meet any of the following criteria will be excluded from study entry:&#xD;
&#xD;
          -  Transformed lymphoma&#xD;
&#xD;
          -  CNS lymphoma&#xD;
&#xD;
          -  Prior treatment with mosunetuzumab&#xD;
&#xD;
          -  Prior stem cell transplant (autologous and allogeneic)&#xD;
&#xD;
          -  History of confirmed progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          -  Known or suspected chronic active Epstein Barr virus (CAEBV), hepatitis B, hepatitis C&#xD;
             (HCV), or Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)&#xD;
&#xD;
          -  Prior solid organ transplantation&#xD;
&#xD;
          -  Current or past history of central nervous system (CNS) disease, such as stroke,&#xD;
             epilepsy, CNS vasculitis, or neurodegenerative disease&#xD;
&#xD;
          -  Clinically significant history of liver disease&#xD;
&#xD;
          -  Prior treatment with radiotherapy within 2 weeks prior to Cycle 1, Day 1 (C1D1)&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
        Exclusion Criteria Specific to Cohort A&#xD;
&#xD;
        Participants in Cohort A who meet the following criteria will be excluded from study entry:&#xD;
&#xD;
        - Prior treatment with chemotherapy, immunotherapy, or biologic therapy 4 weeks prior to&#xD;
        C1D1&#xD;
&#xD;
        Exclusion Criterion Specific to Cohorts B and C&#xD;
&#xD;
        Participants in Cohorts B and C who meet the following criterion will be excluded from&#xD;
        study entry:&#xD;
&#xD;
        - Prior treatment for DLBCL with chemotherapy, immunotherapy, and biologic therapy&#xD;
&#xD;
        Exclusion Criteria Specific to Cohort C&#xD;
&#xD;
        Participants in Cohort C who meet the following criteria will be excluded from study entry:&#xD;
&#xD;
        - Current Grade &gt;1 peripheral neuropathy by clinical examination or demyelinating form of&#xD;
        Charcot-Marie-Tooth disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO40554 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404-2023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center Screening and Prevention</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center; Rush University Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Institute</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Medical Plaza II; Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0934</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708-9963</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carmel medical center</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein-Karem; Clinical Pharmacology Unit</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar- Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laniado Hospital-Sanz Medical Center</name>
      <address>
        <city>Netanya</city>
        <zip>4215000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center-Beilinson Campus</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center; Pharmacy</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z o. o.</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Alergologii</name>
      <address>
        <city>Krakow</city>
        <zip>31-624</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Opolu;Pododdz. Gastroenter., Pododdz. Hematologii</name>
      <address>
        <city>Opole</city>
        <zip>45-372</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii; Klinika Hematologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d Oncologia Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <state>Sevilla</state>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara; Servicio de Hematología</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

